ES2693166T3 - Pirazolopiridina y métodos para tratar las enfermedades retinales degenerativas y la pérdida auditiva asociadas con el síndrome de Usher - Google Patents
Pirazolopiridina y métodos para tratar las enfermedades retinales degenerativas y la pérdida auditiva asociadas con el síndrome de Usher Download PDFInfo
- Publication number
- ES2693166T3 ES2693166T3 ES13849803.5T ES13849803T ES2693166T3 ES 2693166 T3 ES2693166 T3 ES 2693166T3 ES 13849803 T ES13849803 T ES 13849803T ES 2693166 T3 ES2693166 T3 ES 2693166T3
- Authority
- ES
- Spain
- Prior art keywords
- usher
- pharmaceutically acceptable
- compound
- acceptable salt
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010011878 Deafness Diseases 0.000 title claims description 12
- 208000016354 hearing loss disease Diseases 0.000 title claims description 12
- 208000014769 Usher Syndromes Diseases 0.000 title claims description 10
- 230000010370 hearing loss Effects 0.000 title claims description 9
- 231100000888 hearing loss Toxicity 0.000 title claims description 8
- 238000000034 method Methods 0.000 title claims description 7
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 title description 2
- 208000017442 Retinal disease Diseases 0.000 title description 2
- 230000003412 degenerative effect Effects 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims description 12
- 210000001525 retina Anatomy 0.000 claims description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 7
- 201000004569 Blindness Diseases 0.000 claims description 6
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 claims description 4
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102200123931 rs111033258 Human genes 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010001902 amaurosis Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 230000011218 segmentation Effects 0.000 claims 1
- -1 Pyrazolopyridazine Compound Chemical class 0.000 description 6
- 230000004438 eyesight Effects 0.000 description 6
- 230000004393 visual impairment Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 3
- 208000018769 loss of vision Diseases 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 231100000864 loss of vision Toxicity 0.000 description 2
- 230000005043 peripheral vision Effects 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical compound ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- JMRYOSQOYJBDOI-UHFFFAOYSA-N dilithium;di(propan-2-yl)azanide Chemical compound [Li+].CC(C)[N-]C(C)C.CC(C)N([Li])C(C)C JMRYOSQOYJBDOI-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 210000003027 ear inner Anatomy 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- GQZXNSPRSGFJLY-UHFFFAOYSA-N hydroxyphosphanone Chemical compound OP=O GQZXNSPRSGFJLY-UHFFFAOYSA-N 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000000880 retinal rod photoreceptor cell Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718593P | 2012-10-25 | 2012-10-25 | |
| US201261718593P | 2012-10-25 | ||
| US201361775376P | 2013-03-08 | 2013-03-08 | |
| US201361775376P | 2013-03-08 | ||
| PCT/US2013/066938 WO2014066835A1 (en) | 2012-10-25 | 2013-10-25 | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2693166T3 true ES2693166T3 (es) | 2018-12-07 |
Family
ID=50545355
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13849803.5T Active ES2693166T3 (es) | 2012-10-25 | 2013-10-25 | Pirazolopiridina y métodos para tratar las enfermedades retinales degenerativas y la pérdida auditiva asociadas con el síndrome de Usher |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP2912038B1 (enExample) |
| JP (1) | JP6290910B2 (enExample) |
| AU (1) | AU2013334138B2 (enExample) |
| CA (1) | CA2889537C (enExample) |
| ES (1) | ES2693166T3 (enExample) |
| IL (1) | IL238287B (enExample) |
| PL (1) | PL2912038T3 (enExample) |
| TR (1) | TR201816028T4 (enExample) |
| WO (1) | WO2014066835A1 (enExample) |
| ZA (1) | ZA201502654B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2834049C (en) | 2011-04-25 | 2018-05-22 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| EP2911671B1 (en) * | 2012-10-25 | 2018-06-27 | Usher III Initiative | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| WO2022011091A1 (en) | 2020-07-09 | 2022-01-13 | Usher Iii Initiative, Inc. | Treatment of cancer, inflammatory diseases and autoimmune diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2444882A1 (en) * | 2001-04-30 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of gsk-3 and crystal structures of gsk-3.beta. protein and protein complexes |
| US7812166B2 (en) * | 2004-10-29 | 2010-10-12 | Abbott Laboratories | Kinase inhibitors |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| CN101917999A (zh) * | 2007-11-07 | 2010-12-15 | 弗尔德里克斯制药股份有限公司 | 蛋白质运输的调节 |
| NZ603525A (en) * | 2008-06-27 | 2015-02-27 | Celgene Avilomics Res Inc | Pyrimidine based compound and uses thereof |
| CA2834049C (en) * | 2011-04-25 | 2018-05-22 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| EP2911671B1 (en) * | 2012-10-25 | 2018-06-27 | Usher III Initiative | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
-
2013
- 2013-10-25 JP JP2015539867A patent/JP6290910B2/ja active Active
- 2013-10-25 ES ES13849803.5T patent/ES2693166T3/es active Active
- 2013-10-25 AU AU2013334138A patent/AU2013334138B2/en active Active
- 2013-10-25 TR TR2018/16028T patent/TR201816028T4/tr unknown
- 2013-10-25 WO PCT/US2013/066938 patent/WO2014066835A1/en not_active Ceased
- 2013-10-25 CA CA2889537A patent/CA2889537C/en active Active
- 2013-10-25 PL PL13849803T patent/PL2912038T3/pl unknown
- 2013-10-25 EP EP13849803.5A patent/EP2912038B1/en active Active
-
2015
- 2015-04-14 IL IL238287A patent/IL238287B/en active IP Right Grant
- 2015-04-20 ZA ZA2015/02654A patent/ZA201502654B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL238287B (en) | 2018-07-31 |
| TR201816028T4 (tr) | 2018-11-21 |
| EP2912038A4 (en) | 2016-04-20 |
| CA2889537C (en) | 2017-12-12 |
| EP2912038A1 (en) | 2015-09-02 |
| AU2013334138A1 (en) | 2015-05-07 |
| PL2912038T3 (pl) | 2019-02-28 |
| AU2013334138B2 (en) | 2017-07-27 |
| WO2014066835A1 (en) | 2014-05-01 |
| CA2889537A1 (en) | 2014-05-01 |
| IL238287A0 (en) | 2015-06-30 |
| EP2912038B1 (en) | 2018-08-15 |
| JP2015535256A (ja) | 2015-12-10 |
| HK1214263A1 (en) | 2016-07-22 |
| ZA201502654B (en) | 2016-07-27 |
| JP6290910B2 (ja) | 2018-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2687854T3 (es) | Pirazolopiridazinas y métodos para tratar las enfermedades degenerativas de la retina y la pérdida de audición asociada con el síndrome de Usher | |
| Yin et al. | Targeting herpes simplex virus with CRISPR–Cas9 cures herpetic stromal keratitis in mice | |
| Rathore et al. | Effect of formulation factors on in vitro transcorneal permeation of gatifloxacin from aqueous drops | |
| CN102164592B (zh) | 可与核黄素一起使用的增强剂制备用于在圆锥角膜的治疗中进行角膜交联的眼用组合物的用途以及相应眼用组合物 | |
| Yoon et al. | Effect of hydroxychloroquine treatment on dry eyes in subjects with primary Sjögren’s syndrome: a double-blind randomized control study | |
| Nourinia et al. | Repeated injection of methotrexate into silicone oil-filled eyes for grade C proliferative vitreoretinopathy: a pilot study | |
| KR101867791B1 (ko) | 수성 점안액 | |
| UA124698C2 (uk) | Офтальмологічний розчин | |
| ES2625534T3 (es) | Pirazolopiridazinas y métodos para el tratamiento de enfermedades degenerativas de la retina y pérdida de la audición asociadas con el síndrome de Usher | |
| ES2772724T3 (es) | Composición farmacéutica para la prevención y el tratamiento de enfermedades del ojo seco, que contiene imatinib como principio activo | |
| KR20190013877A (ko) | 아트로핀-함유 수성 조성물 | |
| Ye et al. | Cytoprotective effect of hyaluronic acid and hydroxypropyl methylcellulose against DNA damage induced by thimerosal in Chang conjunctival cells | |
| Kim et al. | In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells | |
| ES2848977T5 (es) | Métodos de tratamiento de afecciones oculares | |
| KR20100090278A (ko) | 목시플록사신 하이드로클로라이드 및 덱사메타손 포스페이트를 함유하는 국소용 안과 또는 이과용 용액 제제 | |
| KR20210072039A (ko) | 면역절제 요법 | |
| JP2017165707A (ja) | ドルゾラミドとチモロールと界面活性剤を含有する医薬組成物 | |
| JP2020055799A (ja) | 眼科組成物 | |
| US11464773B2 (en) | Nutlin-3a for treatment of proliferative vitreoretinopathy | |
| Raab et al. | Lacrimal gland abscess in a child as a rare manifestation of IgG4-related disease | |
| Cheung et al. | Infectious keratitis after ocular surface stem cell transplantation | |
| Wenk et al. | Glucocorticoid receptor binding in bovine lens. | |
| Pauly et al. | Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFNγ and toxicological profiles | |
| CN101272765A (zh) | 包含用于治疗疱疹性角膜炎的溴夫定的耐光药物组合物 | |
| Végh et al. | Presence of SARS-CoV-2 on the conjunctival mucosa in patients hospitalized due to COVID-19: Pathophysiological considerations and therapeutic implications |